Work

Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.9510

Authors: Mahrukh M Syeda, JENNIFER M WIGGINS, Broderick Corless, Georgina V. Long, Keith Flaherty, Dirk Schadendorf, Paul D. Nathan, Caroline Robert, Antoni Ribas, Michael A. Davies, Jean Jacques Grob, Eduard Gasal, Matthew Squires, Mahtab Marker, Jan C. Brase, David Polsky

Institutions: NYU Langone Health, The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Essen University Hospital, Mount Vernon Cancer Centre, Institut Gustave Roussy, University of California, Los Angeles, The University of Texas MD Anderson Cancer Center, Aix-Marseille Université, Novartis (Switzerland)

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947516908

Cites:

Cited by: 1

Related to: 10